In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

UCB SA (OTCMKTS:UCBJF – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 ...

Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.

Arthritis in your 20s might seem unusual, but it's becoming more frequent. Check out these 7 warning signs and symptoms of ...

Persistent pain is common in rheumatoid arthritis. But patient-reported outcomes tools can help clinicians determine a care plan.